multiple sclerosis and glp 1 Frontiers The Multifaceted Nature of GLP-1:

Am J Physiol Metab

Available from: Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A

( Figure 5 ) Briefly, SGLT2i inhibits the SGLT receptors in the proximal tubule, which inhibits the reabsorption of glucose from primary urine, resulting in glycosuria and a decrease in HbA1c and fasting glucose levels ( Figure 5 Clinical implications Given the significant cardioprotective effect of SGLT2i and GLP-1RAs, the ADA guidelines state that all diabetic patients with confirmed or subclinical cardiovascular disease should be prescribed a GLP-1RA class or SGLT2i class with proven cardiovascular benefit, regardless of the patients HbA1c level or the presence of other glucose-lowering medications ( Strengths and limitations To the best of our knowledge, this is the first meta-analysis to assess the effects of SGLT2i and GLP-1RAs as first-line therapeutic agents in T2DM patients with low cardiovascular disease risk

Maintain a sense of hope and positive thinking

To support individuals using GLP-1 medications as well as those pursuing weight management without them, brands can focus on formulating products that deliver satiety, nutrition and convenience